Stocks › GLUE
Monte Rosa Therapeutics GLUE
US equityMarket cap rank #3349
$8.64 −$0.27 (-3.03%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $8.64 0.00%
Open$8.73
Prev close$8.91
Day range$8.48 – $9.04
Volume2.52M
Market cap$738.29M
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$54.37M+325.8% YoY
Operating profit-$1.94M+94.1% YoY
Net profit$3.06M+111.3% YoY
Diluted EPS$0.03+109.1% YoY
Free cash flow-$42.54M-142.6% YoY
Operating cash flow-$40.98M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Operating margin-214.5%
Net margin-186.2%
Return on equity-35.3%
Return on assets-22.6%
Return on invested capital-35.1%
Current ratio10.32
Liabilities / assets28.9%
Cash & investments$577.73M
Total debt$32.08M
Net cash (debt)$545.65M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $54.37M | $8.97M | $4.21M | $123.67M | $2.78M |
| Total Operating Revenue | $54.37M | $8.97M | $4.21M | $123.67M | $2.78M |
| Operating Expense | $56.31M | $58.10M | $54.24M | $177.88M | $52.50M |
| Selling and Admin Expenses | $10.94M | $10.13M | $10.18M | $36.38M | $10.52M |
| -General & Admin Expense | $10.94M | $10.13M | $10.18M | $36.38M | $10.52M |
| Research & Development | $45.36M | $47.96M | $44.07M | $141.50M | $41.98M |
| Operating Profit | -$1.94M | -$49.13M | -$50.03M | -$54.21M | -$49.72M |
| Net Non-Operating Interest Income (Expense) | $5.63M | $5.92M | $5.59M | $12.94M | $3.69M |
| Non-Operating Interest Income | $5.63M | $5.92M | $5.59M | $12.94M | $3.69M |
| Other Income (Expense) | $93,000.00 | $25,000.00 | -$8,000.00 | $1.54M | -$50,000.00 |
| Gain on Sale of Security | $93,000.00 | $25,000.00 | -$8,000.00 | $1.48M | -$50,000.00 |
| Special Income (Charges) | $0.00 | $0.00 | $0.00 | $59,000.00 | $0.00 |
| -Gain on Sale of Property/Plant/Equipment | $0.00 | $0.00 | $0.00 | $59,000.00 | $0.00 |
| Pretax Profit | $3.78M | -$43.19M | -$44.45M | -$39.72M | -$46.08M |
| Tax | $716,000.00 | $208,000.00 | $52,000.00 | -$1.10M | $59,000.00 |
| Net Profit | $3.06M | -$43.40M | -$44.50M | -$38.63M | -$46.14M |
| Profit from Continuing Operations | $3.06M | -$43.40M | -$44.50M | -$38.63M | -$46.14M |
| Net Income to Parent Company | $3.06M | -$43.40M | -$44.50M | -$38.63M | -$46.14M |
| Net Income to Common Stockholders | $3.06M | -$43.40M | -$44.50M | -$38.63M | -$46.14M |
| Basic EPS | $0.03 | -$0.43 | -$0.45 | -$0.46 | -$0.70 |
| Diluted EPS | $0.03 | -$0.43 | -$0.45 | -$0.46 | -$0.70 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $697.73M | $691.16M | $736.43M | $448.66M | $448.66M |
| Total Current Assets | $640.07M | $631.41M | $677.55M | $393.19M | $393.19M |
| Cash and Cash Equivalents & Short-Term Investments | $577.73M | $621.10M | $666.22M | $377.10M | $377.10M |
| -Cash and Cash Equivalents | $45.18M | $90.10M | $159.86M | $129.88M | $129.88M |
| -Short Term Investments | $532.55M | $531.00M | $506.36M | $247.22M | $247.22M |
| Receivables | $57.62M | $4.92M | $4.61M | $11.60M | $11.60M |
| -Other Receivables | $57.62M | $4.92M | $4.61M | $11.60M | $11.60M |
| Other Current Assets | $4.72M | $5.38M | $6.72M | $4.48M | $4.48M |
| Total Non-Current Assets | $57.66M | $59.76M | $58.88M | $55.47M | $55.47M |
| Net PPE | $51.98M | $53.99M | $53.10M | $50.37M | $50.37M |
| -Gross PPE | $85.67M | $85.54M | $82.75M | $77.99M | $77.99M |
| -Accumulated Depreciation | -$33.69M | -$31.55M | -$29.64M | -$27.61M | -$27.61M |
| Other Non-Current Assets | $5.69M | $5.77M | $5.78M | $5.10M | $5.10M |
| Total Liabilities | $201.52M | $203.88M | $214.51M | $215.60M | $215.60M |
| Total Current Liabilities | $62.05M | $59.66M | $71.04M | $64.21M | $64.21M |
| Payables | $6.37M | $7.15M | $7.90M | $3.55M | $3.55M |
| -Accounts Payable | $3.35M | $7.15M | $7.90M | $3.55M | $3.55M |
| -Total Tax Payable | $3.02M | – | – | – | – |
| Current Accrued Expenses | $19.12M | $18.30M | $19.31M | $15.12M | $15.12M |
| Short-Term Debt and Capital Lease Obligation | $4.19M | $4.63M | $4.48M | $4.40M | $4.40M |
| -Current Capital Lease Obligation | $4.19M | $4.63M | $4.48M | $4.40M | $4.40M |
| Current Deferred Liabilities | $21.10M | $22.10M | $33.06M | $29.57M | $29.57M |
| Other Current Liabilities | $1.94M | $1.17M | $1.24M | $1.58M | $1.58M |
| Total Non-Current Liabilities | $139.47M | $144.22M | $143.48M | $151.39M | $151.39M |
| Long Term Debt and Capital Lease Obligation | $32.08M | $33.36M | $34.58M | $34.79M | $34.79M |
| -Long Term Capital Lease Obligation | $32.08M | $33.36M | $34.58M | $34.79M | $34.79M |
| Non-Current Deferred Liabilities | $102.26M | $105.62M | $103.64M | $111.33M | $111.33M |
| Employee Benefits | $5.13M | $5.24M | $5.26M | $5.27M | $5.27M |
| Total Equity | $496.21M | $487.28M | $521.92M | $233.06M | $233.06M |
| Stockholders' Equity | $496.21M | $487.28M | $521.92M | $233.06M | $233.06M |
| Capital Stock | $9,000.00 | $9,000.00 | $8,000.00 | $7,000.00 | $7,000.00 |
| -Common Stock | $9,000.00 | $9,000.00 | $8,000.00 | $7,000.00 | $7,000.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | – | – |
| Additional Paid-In Capital | $1.06B | $1.06B | $1.05B | $714.09M | $714.09M |
| Retained Earnings | -$562.05M | -$565.11M | -$521.72M | -$477.21M | -$477.21M |
| Gains/Losses Not Affecting Retained Earnings | -$6.19M | -$5.17M | -$4.75M | -$3.83M | -$3.83M |
| Convertible preferred securities | – | – | $0.00 | $0.00 | $0.00 |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$40.98M | -$44.11M | -$37.37M | -$22.80M | -$43.01M |
| Net cash flow from continuing operations | -$40.98M | -$44.11M | -$37.37M | -$22.80M | -$43.01M |
| Net Income from Continuing Operations | $3.06M | -$43.40M | -$44.50M | -$38.63M | -$46.14M |
| Depreciation & Depletion & Amortization | $2.14M | $1.91M | $2.03M | $8.36M | $2.09M |
| Change in Working Capital | -$52.86M | -$7.63M | $141,000.00 | -$9.19M | -$3.36M |
| -Change in Receivables | -$52.70M | -$311,000.00 | $6.99M | -$11.43M | -$6.64M |
| -Change in Prepaid Assets | $728,000.00 | $1.34M | -$2.92M | $604,000.00 | $1.38M |
| -Change in Payables and Accrued Expense | $4.55M | $717,000.00 | $665,000.00 | -$5.86M | -$1.88M |
| -Change In Other Working Capital | -$5.43M | -$9.37M | -$4.59M | $7.49M | $3.77M |
| Net cash flow from investing | -$4.54M | -$28.86M | -$261.00M | -$101.83M | -$65.07M |
| Net Cash Flow from Continuing Investing Activities | -$4.54M | -$28.86M | -$261.00M | -$101.83M | -$65.07M |
| Net PPE Purchase and Sale | -$1.56M | -$4.72M | -$1.87M | -$4.70M | -$767,000.00 |
| Net Investment Purchase and Sale | -$2.98M | -$24.14M | -$259.13M | -$97.13M | -$64.30M |
| Financing Cash Flow | $568,000.00 | $3.21M | $328.34M | $30.35M | $29.62M |
| Net Cash Flow from Continuing Financing Activities | $568,000.00 | $3.21M | $328.34M | $30.35M | $29.62M |
| Net Common Stock Issuance | $0.00 | $0.00 | $324.30M | $23.89M | $23.89M |
| Proceeds from Stock Option Exercised | $568,000.00 | $3.21M | $4.52M | $6.46M | $5.73M |
| Net Other Financing Charges | $0.00 | $0.00 | -$487,000.00 | – | – |
| Ending Cash Balance | $50.10M | $95.04M | $164.81M | $134.84M | $134.84M |
| Net Change in Cash | -$44.95M | -$69.76M | $29.97M | -$94.28M | -$78.46M |
| Beginning Cash Balance | $95.04M | $164.81M | $134.84M | $229.12M | $213.29M |
| Free Cash Flow | -$42.54M | -$48.84M | -$39.24M | -$27.50M | -$43.78M |
| Gain/Loss from Continuing Operations | – | – | – | -$59,000.00 | $0.00 |
No comments yet — be the first to weigh in on GLUE.
Sign in to join the discussion.